RESULTS:
Gel immunoagglutination revealed group A red blood cells and a mixed-field reaction for the D phenotype, with a predominant D-negative population and a small subset of circulating red blood cells carrying the D antigen. Subsequent genomic microarray single nucleotide polymorphism profiling revealed copy-neutral loss of heterozygosity of chromosome 1 p36.33-p34.2, a known molecular mechanism underlying fibrotic progression of MPL-mutated essential thrombocythemia. The chromosomal region affected by this copy-neutral loss of heterozygosity encompassed the RHD, RHCE, and MPL genes. We propose a model of chronological molecular events that is supported by RHD zygosity assays in peripheral lymphoid and myeloid-derived cells.
CONCLUSION:
Copy-neutral loss of heterozygosity events that lead to clonal selection and myeloid malignant progression may also affect the expression of adjacent unrelated genes, including those encoding for blood group antigens. Detection of mixed-field reactions and investigation of discrepant blood typing results are important for proper transfusion support of these patients and can provide useful surrogate markers of myeloproliferative disease progression.
A 65-year-old female with a 17-year history of essential thrombocythemia (ET) who had progression to secondary myelofibrosis was admitted for human leukocyte antigen-matched allogeneic stem cell transplantation under an institutional review board-approved clinical protocol. The patient had never received transfusions before she underwent transplantation.
Routine pretransplantation evaluation using gelcolumn agglutination (MTS ABD Gel Card, ID Gel System; Ortho) revealed the patient's blood type as group A, with mixed-field reactivity detected for the D antigen (Fig. 1A) . The mixed-field reactivity appeared to represent a predominant D-negative red blood cell (RBC) population, with a small subset of circulating RBCs that agglutinated with the addition of anti-D (MS20; Millipore Ltd.) (Fig. 1A , black and red arrows, respectively). Transfusion history gathered from an outside facility indicated that the patient had been classified as blood group A D-negative (using an automated platform with a microplate-hemagglutination technique) when she underwent splenectomy 2 months before this admission. A retained donor-identification card produced by the patient revealed that she was typed as blood group A D-positive when she donated blood in her youth.
A review of the patient's previous molecular marrow studies revealed normal female 46XX karyotype by Gbanding as well as detection of an MPL W515K mutation (a tryptophan-to-lysine substitution at codon 151 in the myeloproliferative leukemia proto-oncogene, thrombopoietin receptor [MPL] gene) early in the course of her disease. The MPL gene, located in chromosome 1p, encodes for the thrombopoietin receptor and is mutated in approximately 5% of patients with ET.
1,2 The patient's marrow always tested negative for JAK2 (Janus kinase 2) mutation and was negative for monosomy 7, trisomy 8, and deletions 5q31, 7q31, and 20q12 by fluorescence in situ hybridization.
To further explore the possibility of genomic dosage aberrations, high-density genomic microarray single nucleotide polymorphism (SNP) profiling of the patient's marrow was performed on admission (research sample collection protocol NCT00071045). This assay, based on genomic hybridization to 1.9 million probes to investigate approximately 750,000 SNPs, revealed copy-neutral loss of heterozygosity (CN-LOH) of chromosome 1p36.33-p34.2 ( Fig. 2A) , a known molecular mechanism underlying fibrotic progression of MPL-mutated ET. 3 The chromosomal region Fig. 2A) .
To test the proposed model, CD31 T lymphocytes and CD11b1/CD141 monocytes were isolated from the patient's peripheral blood by flow sorting. Genomic DNA was extracted from both populations, and RHD zygosity was investigated as a quantitative ratio of RHD Exons 5 and 7 to an internal control gene. 4 T lymphocytes, which are not expected to arise from the myeloproliferative clone, revealed an RHD/control ratio of 0.5, consistent with congenital hemizygosity for the RHD gene. Circulating peripheral monocytes, on the other hand, had a lower RHD/control ratio of 0.3, consistent with complete absence of the RHD gene in a subset of these cells, as predicted by our model. The patient underwent myeloablative allogeneic stem cell transplantation with a conditioning regimen consisting of fludarabine, cyclophosphamide, and total body irradiation. She received an ex vivo, T celldepleted, CD341 selected peripheral blood stem cell graft (9.4 3 10 6 /kg CD341 cells and 5 3 10 4 /kg CD3 T cells) from a group A, D-positive donor. The patient achieved successful engraftment with 100% myeloid chimerism by Day 14. Her marrow biopsy showed normal trilineage hematopoiesis with significantly reduced fibrosis, and genomic microarray SNP profiling was normalized 2 months after transplantation. RhD mosaicism was no longer identified 1 year after transplantation (Fig. 1B) . these patients and unnecessary depletion of the Dnegative blood supply.
DISCUSSION

